Clinical trial registry record

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 11, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04959175
Last registry update
June 11, 2026
Status
Recruiting
Phase
Phase 1, Phase 2
Sponsor
National Cancer Institute (NCI)
Enrollment
320
Countries
United States
Match confidence
62%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
NA · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
320
Population
ALL · 12 Years to 85 Years
Duration
2021-09-23 to 2027-04-30
Intervention
Mycophenolate Mofetil; Allogeneic HSCT; Fludarabine; Sirolimus; Filgrastim; Cyclophosphamide; Mesna; Total Body Irradiation (TBI)
Comparator
Donors
Outcomes measured
determine if optimal dose of PTCy to prevent grade III-IV acute GVHD (aGVHD) at day +60 — 60 days; Grade III-IV acute GVHD at day 100 and 200 — 100 days/200 days; Grade II-IV acute GVHD at day 100 and 200 — 100 days/200 days; Rate of Fried s Frailty Phenotypes (FP) — 1 year; Chronic GVHD at one year — 1 year; Progression/relapse at one year — 1 year; Non-relapse mortality at 100 days and one year — 100 days and 1 year; Overall survival, progression-free survival, and disease-free survival at one year — 1 year; Estimation of platelet engraftment, neutrophil engraftment. — day 28 and day 100
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 62% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 62%Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON